Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

The clinical relevance of BAALC and ERG expression levels in pediatric AML.

Hermkens MC, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Baruchel A, Stary J, Reinhardt D, Zimmerman M, de Haas V, Pieters R, Zwaan CM.

Leukemia. 2013 Mar;27(3):735-7. doi: 10.1038/leu.2012.233. Epub 2012 Aug 16. No abstract available.

PMID:
22895118
2.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD.

Blood. 2010 Dec 16;116(25):5660-9. doi: 10.1182/blood-2010-06-290536. Epub 2010 Sep 14.

3.

Relation of BAALC and ERG Gene Expression with Overall Survival in Acute Myeloid Leukemia Cases.

Rashed RA, Kadry DY, El Taweel M, Abd El Wahab N, Abd El Hameed T.

Asian Pac J Cancer Prev. 2015;16(17):7875-82.

4.

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2009 Jul 1;27(19):3198-204. doi: 10.1200/JCO.2008.20.6110. Epub 2009 May 18.

5.

ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.

Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A, Berdel WE, Büchner T, Wörmann B, Mansmann U, Braess J, Spiekermann K, Hiddemann W, Buske C, Bohlander SK.

J Clin Oncol. 2009 Oct 20;27(30):5031-8. doi: 10.1200/JCO.2008.20.5328. Epub 2009 Sep 14.

PMID:
19752345
6.

Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia.

Haferlach C, Kern W, Schindela S, Kohlmann A, Alpermann T, Schnittger S, Haferlach T.

Genes Chromosomes Cancer. 2012 Mar;51(3):257-65. doi: 10.1002/gcc.20950. Epub 2011 Nov 10.

PMID:
22072540
7.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD.

J Clin Oncol. 2008 Nov 1;26(31):5078-87. doi: 10.1200/JCO.2008.17.5554. Epub 2008 Sep 22. Erratum in: J Clin Oncol. 2008 Dec 20;26(36):6021.

8.

High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrózek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B Study.

J Clin Oncol. 2007 Aug 1;25(22):3337-43. Epub 2007 Jun 18.

PMID:
17577018
9.

BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis.

Eid MA, Attia M, Abdou S, El-Shazly SF, Elahwal L, Farrag W, Mahmoud L.

Int J Lab Hematol. 2010 Apr;32(2):197-205. doi: 10.1111/j.1751-553X.2009.01168.x. Epub 2009 Jun 23.

PMID:
19555438
10.

Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.

Baldus CD, Martus P, Burmeister T, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK.

J Clin Oncol. 2007 Aug 20;25(24):3739-45. Epub 2007 Jul 23.

PMID:
17646667
11.

Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.

Thol F, Yun H, Sonntag AK, Damm F, Weissinger EM, Krauter J, Wagner K, Morgan M, Wichmann M, Göhring G, Bug G, Ottmann O, Hofmann WK, Schambach A, Schlegelberger B, Haferlach T, Bowen D, Mills K, Ganser A, Heuser M.

Ann Hematol. 2012 Aug;91(8):1221-33. doi: 10.1007/s00277-012-1457-7. Epub 2012 Apr 10.

PMID:
22488406
12.

Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia.

Najima Y, Ohashi K, Kawamura M, Onozuka Y, Yamaguchi T, Akiyama H, Sakamaki H.

Int J Hematol. 2010 May;91(4):636-45. doi: 10.1007/s12185-010-0550-8. Epub 2010 Apr 8.

PMID:
20376583
13.

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.

Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD; Cancer and Leukemia Group B (CALGB).

Blood. 2008 Jun 1;111(11):5371-9. doi: 10.1182/blood-2007-11-124958. Epub 2008 Mar 31.

14.
15.

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD.

J Clin Oncol. 2005 Dec 20;23(36):9234-42. Epub 2005 Nov 7.

PMID:
16275934
16.

Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia.

Zhou JD, Yang L, Zhang YY, Yang J, Wen XM, Guo H, Yao DM, Ma JC, Chen Q, Lin J, Qian J.

Med Oncol. 2015 Jan;32(1):386. doi: 10.1007/s12032-014-0386-9. Epub 2014 Nov 27.

PMID:
25428390
17.

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW, Sun Z, Tallman MS, Patel J, Gönen M, Abdel-Wahab O, Levine RL, Estey EH.

Leukemia. 2015 Oct;29(10):2104-7. doi: 10.1038/leu.2015.76. Epub 2015 Mar 16. No abstract available.

18.

Expression profiling of cancer-related galectins in acute myeloid leukemia.

El Leithy AA, Helwa R, Assem MM, Hassan NH.

Tumour Biol. 2015 Sep;36(10):7929-39. doi: 10.1007/s13277-015-3513-0. Epub 2015 May 9.

PMID:
25953264
19.

Evaluation of rs62527607 [GT] single nucleotide polymorphism located in BAALC gene in children with acute leukemia using mismatch PCR-RFLP.

Nadimi M, Rahgozar S, Moafi A, Tavassoli M, Mesrian Tanha H.

Cancer Genet. 2016 Jul-Aug;209(7-8):348-53. doi: 10.1016/j.cancergen.2016.06.005. Epub 2016 Jun 16.

PMID:
27372260
20.

Supplemental Content

Support Center